The Queen's Unstoppable Comeback
It's official: Serena Williams is lacing up her tennis shoes once more. Her decision to return at Queen's Club after a four-year hiatus has sent shockwaves through the tennis world. Fans are buzzing, eager to see if the legendary athlete can once again dominate the court.
This comeback isn't just about her athletic prowess; it's intricately linked to her journey with modern health solutions, specifically GLP-1 medications.
Serena's Health Journey: Unpacking the GLP-1 Connection
Serena Williams has been transparent about her use of Zepbound, a GLP-1 drug, for weight management and overall health. She's become a prominent ambassador for Ro, a digital health platform that provides access to these medications. Her partnership with Ro and her candid sharing of personal health data have put GLP-1s squarely in the spotlight of elite sports.
What Exactly Are GLP-1 Drugs?
GLP-1s, or glucagon-like peptide-1 receptor agonists, are medications initially developed for Type 2 diabetes. They mimic a natural gut hormone, which helps suppress appetite, reduce cravings, and regulate blood sugar. Popular examples include semaglutides (Ozempic, Wegovy) and tirzepatides (Mounjaro, Zepbound).
The Ro Connection: More Than Just an Endorsement
Williams formally partnered with Ro in 2025, starring in their
